Literature DB >> 7905005

High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma.

T A Willey1, E J Bekos, R C Gaver, G F Duncan, L K Tay, J H Beijnen, R H Farmen.   

Abstract

An isocratic high-performance liquid chromatographic method has been developed and validated for the quantitative determination of paclitaxel (Taxol), a novel antimitotic, anticancer agent, in human plasma. The analysis required 0.5 ml of plasma, and was accomplished by detection of the UV absorbance of paclitaxel at 227 nm following extraction and concentration. The method involved extraction of paclitaxel from plasma, buffered with 0.5 ml of 0.2 M ammonium acetate (pH 5.0), onto 1-ml cyano Bond Elut columns. The eluent was evaporated under nitrogen and low heat, and reconstituted with the mobile phase, acetonitrile-methanol-water (4:1:5, v/v/v) containing 0.01 M ammonium acetate (pH 5.0). The samples were chromatographed on a reversed-phase octyl 5 microns column. The retention time of paclitaxel was 10 min. The validated quantitation range of the method was 10-1000 ng/ml (0.012-1.17 microM) of paclitaxel in plasma. Standard curve correlation coefficients of 0.995 or greater were obtained during validation experiments and analysis of clinical study samples. The observed recovery for paclitaxel was 83%. Epitaxol, a biologically active stereoisomer, and baccatin III, a degradation product, were also chromatographically separated from taxol by this assay. The method was applied to samples from a clinical study of paclitaxel in cancer patients, providing a pharmacokinetic profiling of paclitaxel.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905005     DOI: 10.1016/0378-4347(93)80100-i

Source DB:  PubMed          Journal:  J Chromatogr


  12 in total

1.  Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel.

Authors:  Deepti Pandita; Alka Ahuja; Viney Lather; Biju Benjamin; Tathagata Dutta; Thirumurthy Velpandian; Roop Krishen Khar
Journal:  AAPS PharmSciTech       Date:  2011-06-03       Impact factor: 3.246

2.  Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.

Authors:  Junping Wang; Dimitry Mongayt; Vladimir P Torchilin
Journal:  J Drug Target       Date:  2005-01       Impact factor: 5.121

3.  Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure.

Authors:  Mari Jiko; Ikuko Yano; Masahiro Okuda; Ken-ichi Inui
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

4.  Release kinetics study of poorly water-soluble drugs from nanoparticles: are we doing it right?

Authors:  Sara A Abouelmagd; Bo Sun; Alice C Chang; Youn Jin Ku; Yoon Yeo
Journal:  Mol Pharm       Date:  2015-02-17       Impact factor: 4.939

5.  Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.

Authors:  Gaurav Bajaj; Mi Ran Kim; Sulma I Mohammed; Yoon Yeo
Journal:  J Control Release       Date:  2011-12-09       Impact factor: 9.776

6.  Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.

Authors:  Kai Jie Chen; Wan Yi Chen; Xia Chen; Yi Ming Jia; Gui Qin Peng; Li Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-05-17       Impact factor: 2.441

7.  Development of an indirect competitive enzyme-linked immunosorbent assay (icELISA) using highly specific monoclonal antibody against paclitaxel.

Authors:  Zhi Chao; Mingming Tan; Madan Kumar Paudel; Seiichi Sakamoto; Liling Ma; Kaori Sasaki-Tabata; Hiroyuki Tanaka; Yukihiro Shoyama; Lijiang Xuan; Satoshi Morimoto
Journal:  J Nat Med       Date:  2012-09-25       Impact factor: 2.343

8.  Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

Authors:  M Joerger; A D R Huitema; M T Huizing; P H B Willemse; A de Graeff; H Rosing; J H M Schellens; J H Beijnen; J B Vermorken
Journal:  Br J Clin Pharmacol       Date:  2007-11       Impact factor: 4.335

9.  Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.

Authors:  A Sparreboom; M T Huizing; J J Boesen; W J Nooijen; O van Tellingen; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 10.  Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.

Authors:  Hend M Nawara; Said M Afify; Ghmkin Hassan; Maram H Zahra; Akimasa Seno; Masaharu Seno
Journal:  Biomedicines       Date:  2021-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.